Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo.
about
Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Doxorubicin and anti-VEGF siRN ...... therapy in vitro and in vivo.
@en
Doxorubicin and anti-VEGF siRN ...... therapy in vitro and in vivo.
@nl
type
label
Doxorubicin and anti-VEGF siRN ...... therapy in vitro and in vivo.
@en
Doxorubicin and anti-VEGF siRN ...... therapy in vitro and in vivo.
@nl
prefLabel
Doxorubicin and anti-VEGF siRN ...... therapy in vitro and in vivo.
@en
Doxorubicin and anti-VEGF siRN ...... therapy in vitro and in vivo.
@nl
P2093
P2860
P356
P1476
Doxorubicin and anti-VEGF siRN ...... r therapy in vitro and in vivo
@en
P2093
P2860
P304
P356
10.2147/IJN.S162939
P407
P577
2018-06-27T00:00:00Z